Microdosing Contraindications

18+ only — This guide covers adult physiology and adult-only substances.

A microdosing contraindication is a medical condition, psychiatric history, or concurrent medication that makes sub-perceptual dosing of psychedelics inadvisable or outright dangerous. Most online guides focus on microdosing protocols and benefits — the stuff that gets clicks. This article on microdosing contraindications is the less glamorous but arguably more important counterpart: a reference for when you should not microdose, even if you want to. The research base here is still thin (most contraindication lists are extrapolated from full-dose studies or case reports rather than dedicated microdosing trials), but what we do know points to some clear red lines (Kuypers et al., 2019).

Primary Microdosing Contraindications at a Glance

The table below groups known and suspected microdosing contraindications by category. "Established" means clinical evidence or strong pharmacological reasoning supports the concern. "Suspected" means case reports, theoretical risk, or expert consensus without controlled trial data — which, given how young microdosing research is, covers a lot of ground.

That table is your quick reference for microdosing contraindications. Below, we unpack each category so you understand why these matter, not just that they do.

Psychotic Spectrum Disorders: The Hardest Red Line

Psychotic spectrum disorders represent the most absolute microdosing contraindication, supported by both clinical evidence and pharmacological reasoning (Breeksema et al., 2022). If you have a personal history of schizophrenia, schizoaffective disorder, or psychosis NOS, microdosing is off the table. Full stop. This isn't a "proceed with caution" situation — it's a "don't proceed" one. Psilocybin and LSD both act on serotonin 5-HT2A receptors, and activation of these receptors can destabilise perception and cognition in individuals already vulnerable to psychotic breaks (Breeksema et al., 2022).

AZARIUS · Psychotic Spectrum Disorders: The Hardest Red Line

Family history matters too. A 2022 systematic review by Breeksema et al. published in the Journal of Psychopharmacology noted that most clinical psilocybin trials explicitly exclude participants with first-degree relatives who have psychotic disorders (Breeksema et al., 2022). They do this not because a single microdose will definitely cause a psychotic episode, but because the risk-to-benefit ratio is unacceptable when the downside is that severe.

The tricky part: some people with psychotic vulnerability don't know about their family history, or their own prodromal symptoms haven't been recognised yet. Microdosing communities sometimes frame this as "rare," and statistically it is — roughly 1% of the general population develops schizophrenia. But if you're in that 1%, a sub-perceptual dose isn't sub-consequential.

Bipolar Disorder: Mania Risk

Bipolar disorder is a well-established microdosing contraindication, particularly type I, due to the risk of serotonergic substances triggering manic episodes (Anderson et al., 2019). The worry isn't psychosis per se (though that can happen in severe manic episodes) — it's mania induction. Serotonergic substances can tip the balance in individuals with bipolar vulnerability, triggering hypomanic or full manic episodes that may take weeks to resolve and can have devastating real-world consequences (Anderson et al., 2019).

AZARIUS · Bipolar Disorder: Mania Risk

A retrospective survey by Anderson et al. (2019) found that individuals with bipolar disorder who microdosed reported more negative outcomes than those without mood disorders (Anderson et al., 2019). The numbers were small, the methodology was self-report, and the effect wasn't dramatic — but it's consistent with what psychiatrists have been cautious about for decades regarding serotonergic agents and bipolar patients.

If you're on mood stabilisers for bipolar disorder, you're also dealing with potential medication interactions (lithium being the most dangerous — more on that below). This is one of the microdosing contraindications where the overlap between psychiatric risk and medication risk compounds the danger.

Cardiac Concerns: The 5-HT2B Question

Chronic 5-HT2B receptor agonism is associated with cardiac valvulopathy, and both psilocin and LSD activate this receptor — making pre-existing heart valve conditions a serious microdosing contraindication (EMCDDA, 2023; Petrie-Flom Center, 2023). This one gets less attention than it deserves. The same mechanism got fenfluramine (part of "fen-phen") pulled from the market in the 1990s after it caused valvular heart disease (VHD) in long-term users. The EMCDDA has noted the general cardiovascular risks associated with serotonergic substances, and this concern extends to repeated low-dose use (EMCDDA, 2023).

AZARIUS · Cardiac Concerns: The 5-HT2B Question

A 2023 analysis published by researchers at Harvard's Petrie-Flom Center flagged this as a specific concern for microdosing protocols that involve repeated dosing over months or years (Petrie-Flom Center, 2023). The key distinction: a single full dose of psilocybin activates 5-HT2B receptors for a few hours. A microdosing protocol — say, every third day for six months — means chronic, intermittent receptor activation. Nobody has studied whether this cumulative exposure is enough to cause valve changes in humans.

The honest answer is that we don't have the data to say it's safe or unsafe at microdose levels over long periods. What we do know is that the pharmacological mechanism for concern exists, and that individuals with pre-existing valvular conditions are taking on additional unknown risk. If you've been diagnosed with mitral valve prolapse, aortic regurgitation, or any form of VHD, this theoretical risk becomes a practical reason to avoid long-term microdosing protocols. Compare this to full-dose psychedelic therapy, where the total number of sessions is small (typically one to three) and 5-HT2B exposure is brief — the cumulative receptor load from months of microdosing could theoretically exceed that of a few full-dose sessions.

Medication Interactions: The Big Three

Lithium, MAOIs, and SSRIs/SNRIs are the three medication categories most relevant to microdosing contraindications, ranging from absolute red lines to strong cautions depending on the substance involved (Fadiman & Korb, 2019). Full interaction tables live in the dedicated microdosing and medication interactions article on the Azarius wiki — here we cover the three interactions that cross from "caution" into "contraindication" territory.

Lithium

Lithium combined with serotonergic psychedelics is the most dangerous interaction in this space. Case reports describe seizures, loss of consciousness, and cardiac events. The mechanism involves lithium's effects on serotonin signalling compounding with the serotonergic action of psilocybin or LSD. Dr. James Fadiman and Sophia Korb, who compiled one of the largest observational datasets on microdosing, list lithium as an absolute contraindication — the only medication they categorise that way (Fadiman & Korb, 2019).

If you're on lithium: do not microdose. Do not reduce your lithium to microdose. Do not stop lithium to microdose. Lithium discontinuation itself carries serious risks including rebound mania.

MAOIs

Monoamine oxidase inhibitors (phenelzine, tranylcypromine, and to a lesser extent moclobemide) prevent the breakdown of serotonin. Combining them with substances that flood serotonin receptors creates a risk of serotonin syndrome — a potentially fatal condition characterised by hyperthermia, muscle rigidity, and autonomic instability. This applies to pharmaceutical MAOIs and also to natural MAOIs like those found in ayahuasca brews (harmine, harmaline). Even at microdose levels, the potentiation from MAO inhibition makes the effective dose unpredictable. This is one of the microdosing contraindications where the pharmacology is clear enough that "suspected" effectively means "assumed."

SSRIs and SNRIs

This one's more of a grey zone than the two above, which is why it sits at "suspected" rather than "established" in the microdosing contraindications table. SSRIs (fluoxetine, sertraline, citalopram, etc.) and SNRIs (venlafaxine, duloxetine) both occupy serotonin receptor sites. In practice, many people report that SSRIs simply blunt the effects of microdosing, making it feel like nothing. But the theoretical risk of serotonin syndrome exists, particularly with higher microdoses or when combining multiple serotonergic agents. A 2021 survey-based study by Kopra et al. found that participants combining psychedelics with antidepressants reported slightly more adverse effects, though the differences were small (Kopra et al., 2021).

The bigger concern here is practical: people sometimes reduce or stop their antidepressants to "make the microdose work." Abrupt SSRI discontinuation causes withdrawal syndrome (brain zaps, emotional instability, flu-like symptoms), and doing this without medical supervision to pursue an unproven protocol is a genuinely bad idea.

Pregnancy, Breastfeeding, and Developing Brains

There are zero controlled studies on microdosing during pregnancy, making this a precautionary but firm microdosing contraindication (Kuypers et al., 2019). The serotonin system plays a critical role in foetal brain development, and introducing exogenous 5-HT2A agonists during this process is an uncontrolled experiment on a developing nervous system. The precautionary principle applies here without much debate (Kuypers et al., 2019).

The same logic extends to breastfeeding (psilocin's transfer into breast milk hasn't been quantified) and to adolescents. The human brain continues significant development until roughly age 25, with the prefrontal cortex being the last region to mature. Introducing repeated serotonergic stimulation during this window is not something any researcher has endorsed. The Beckley Foundation's microdosing research programme has specifically highlighted the absence of developmental safety data as a critical gap requiring future study (Beckley Foundation, 2023).

Anxiety Disorders: A Subtler Microdosing Contraindication

Microdosing can make anxiety worse in a meaningful minority of users, making severe anxiety disorders — particularly panic disorder — a notable microdosing contraindication (Kuypers et al., 2019). This is where things get complicated, because many people microdose specifically for anxiety. Survey data from Fadiman and Korb's ongoing observational project suggests that a majority of microdosers report reduced anxiety — but a meaningful minority report increased anxiety, particularly during the first few sessions or when doses creep above the sub-perceptual threshold.

According to a 2019 systematic review by Kuypers et al. published in Psychopharmacology, side effects of microdosing include increases in anxiety and physiological discomfort, with most adverse effects being mild and transient (Kuypers et al., 2019). For someone with generalised anxiety, that might be manageable. For someone with panic disorder, even a mild, transient increase in anxiety can trigger a full panic attack — and the anticipation of that happening can create a self-reinforcing cycle.

This isn't an absolute contraindication in the way psychotic disorders or lithium use are. It's more of a strong caution: if you have severe or poorly controlled anxiety, microdosing is not the low-risk intervention it's sometimes marketed as.

Practical Screening Before You Buy

Before you order or buy any microdosing product — whether psilocybin truffles, LSD derivatives, or anything else — run through this basic self-screening for microdosing contraindications. It won't replace a conversation with a healthcare professional, but it catches the most common red flags.

• Do you or a first-degree relative have a history of psychosis, schizophrenia, or schizoaffective disorder? → Do not microdose.
• Do you have bipolar disorder (type I or II)? → Do not microdose.
• Are you currently taking lithium? → Do not microdose under any circumstances.
• Are you on an MAOI? → Do not microdose.
• Do you have a diagnosed heart valve condition? → Discuss with your cardiologist before considering any protocol.
• Are you pregnant, breastfeeding, or under 18? → Do not microdose.
• Are you on SSRIs or SNRIs? → Talk to your prescriber. Do not stop your medication to microdose.

If none of the above microdosing contraindications apply to you and you want to get started, the main microdosing guide on the Azarius wiki covers protocols, dosing, and what to expect. For those looking to buy microdosing products, the Azarius smartshop carries psilocybin truffles (including the popular Microdosing XP Truffles) and related items in the smartshop category — but we'd rather you read this page first and the product page second. The psilocybin truffles product pages have dosing specifics for each product we carry.

Gaps in the Evidence

Most of the microdosing contraindications above are extrapolated from full-dose psychedelic research, general pharmacology, or observational survey data. As of early 2025, only a handful of randomised controlled trials have specifically studied microdosing, and most of those excluded participants with the very conditions we're discussing here — meaning we have almost no direct evidence about what happens when someone with bipolar disorder or a cardiac condition microdoses. A 2022 systematic review published in Scientific Reports found that the existing microdosing literature is too limited to draw firm conclusions about either efficacy or safety in clinical populations (Rootman et al., 2022). The Beckley Foundation has also highlighted the need for more rigorous clinical trials that include rather than exclude participants with common comorbidities (Beckley Foundation, 2023). The EMCDDA's ongoing monitoring of psychoactive substance trends similarly notes the lack of long-term safety data for sub-perceptual dosing regimens (EMCDDA, 2023). The absence of evidence of harm is not evidence of absence of harm — a distinction that matters when you're making decisions about your own brain chemistry.

Compared to full-dose psychedelic therapy — where contraindication screening is handled by clinicians in controlled settings — microdosing puts the screening responsibility entirely on the individual. That's a meaningful difference. In a clinical psilocybin trial, you'd be excluded at intake if you had any of the conditions listed above. When you buy truffles from a smartshop, nobody runs that checklist for you. This article is our attempt to fill that gap.

For a complete overview of how microdosing works and where the evidence currently stands, see the main microdosing guide on the Azarius wiki. For specific medication interactions beyond the three covered here, the microdosing and medication interactions article goes into detail with Fadiman and Korb's compiled list. If you want to order microdosing products after reviewing these microdosing contraindications, the Azarius smartshop has psilocybin truffles, microdosing strips, and related items with dosing specifics on each product page.

Last updated: April 2026